Which peptides are studied for sexual and reproductive health?

Short answer

8 profiles here are grouped under “Sexual and reproductive health”: 7 FDA-approved and 1 not FDA-approved.

Each entry below quotes its profile and links to the full answer there.

FDA-approved 7

Not FDA-approved 1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    VYLEESI (bremelanotide) injection · SPL version 1 · published 2025-11-18 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  2. 2
    Drugs@FDA application NDA210557 · original submission status AP · 2019-06-21 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  3. 3
    CETROTIDE (cetrorelix acetate) kit · SPL version 18 · published 2025-09-29 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  4. 4
    Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  5. 5
    Ganirelix acetate injection, solution (Organon LLC) · SPL version 10 · published 2026-10-12 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  6. 6
    Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  7. 7
    Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  8. 8
    Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 16, 2026

  9. 9
    ZOLADEX (goserelin) implant · SPL version 9 · published 2026-03-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  10. 10
    Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  11. 11
    ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  12. 12
    Drugs@FDA application NDA019010 · original submission status AP · 1985-04-09 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  13. 13
    Drugs@FDA application NDA019732 · original submission status AP · 1989-01-26 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  14. 14
    Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  15. 15
    Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  16. 16
    Drugs@FDA application NDA213225 · original submission status AP · 2026-08-26 · dataset 2026-11-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked November 15, 2026

  17. 17
    SYNAREL (nafarelin acetate) nasal solution · SPL version 23 · published 2026-03-10 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  18. 18
    Drugs@FDA: SYNAREL (nafarelin acetate), NDA 019886 · original approval February 13, 1990 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  19. 19
    FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  20. 20
    October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  21. 21
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026